GT Medical Announces Seven Clinical Data Presentations of GammaTile® Therapy for Brain Tumors at the 2021 Annual Meeting of the Society for Neuro-Oncology

Data Highlights How FDA-Cleared Treatment Can Improve Safety and Efficacy Outcomes In Patients With Brain Tumors

News provided by

Nov 18, 2021, 09:00 ET

TEMPE, Ariz., Nov. 18, 2021 /PRNewswire/ -- GT Medical Technologies, Inc. a company dedicated to improving the lives of patients with brain tumors, today announced upcoming presentations related to its breakthrough GammaTile^® Therapy at the 26^th Annual Meeting of the Society for Neuro-Oncology (SNO) being held in Boston November 18-21, 2021. In total, GammaTile will be showcased in seven clinical presentations as well as an Industry-Sponsored Symposium.

"We look forward to sharing updated data, clinical experiences of GammaTile users, and ongoing trials evaluating GammaTile Therapy with our neuro-oncology colleagues at the SNO conference this week," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "These presentations add to the mounting clinical evidence supporting the use of GammaTile Therapy in patients with brain tumors."

A list of educational presentations and their respective authors are below. The full text of these presentations is available in the November supplement of Neuro-Oncology, the official journal of the Society for Neuro-Oncology.

Poster Session: Friday, November 19th, 7:30 PM – 9:30 PM, Exhibit Hall D

A Multicenter Observational Study Of Cs-131 Seeds Embedded In A Collagen Carrier Tile For Newly Diagnosed And Recurrent Operable Intracranial Neoplasms –Trial In Progress, Erin Dunbar, MD
Successful Safety And Efficacy Of GammaTile Intracranial Brachytherapy Implanted During Awake Craniotomy, Ulysses G. Gardner, Jr., MD, MBA
Phase III Multicenter RCT Of Post-Surgical Stereotactic Radiotherapy Versus Surgically Targeted Radiation Therapy For The Treatment Of Large Newly Diagnosed Brain Metastases – Trial In Progress, Jeffrey S. Weinberg, MD
Access To Specialty Radiation Care For Patients With Resectable Brain Tumors, Mehee Choi, MD

Lunch Independent Symposium Session: Saturday, November 20th, 12:45 PM – 1:45 PM

GammaTile Therapy: Surgically Targeted Radiation Therapy For Brain Tumors, David Brachman, MD, Clark C. Chen, MD, PhD, Erin Dunbar, MD, Brandon Imber, MD

Abstract Session: Sunday, November 21st, 10:10 AM – 10:15 AM, Room 208

First Experience With Maximal Safe Resection And GammaTile Brachytherapy As Treatment For Recurrent Glioblastoma, Clark C. Chen, MD, PhD

Concurrent Session: Sunday, November 21st, 11:50 AM – 12:10 PM, Ballroom C

Revisiting Brachytherapy In The Treatment Of Recurrent Glioblastoma, Peter Nakaji, MD

Published Abstract Available Online

Resection And Surgically Targeted Radiation Therapy For Treatment Of Locally Recurrent GBM In 28 Prospectively Treated Patients, Kris Smith, MD

About GT Medical Technologies, Inc.

Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. GammaTiles consist of resorbable collagen embedded with radiation sources and are implanted during the last five minutes of brain tumor resection procedures, They provide an immediate, dose-intense treatment to eliminate residual tumor cells. This "one and done" procedure allows patients to receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.

SOURCE GT Medical Technologies